Claims for Patent: 10,239,922

Summary for Patent: 10,239,922

Title:	Fusion proteins of superfolder green fluorescent protein and use thereof
Abstract:	The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.
Inventor(s):	Liu; Wenshe (College Station, TX), Wan; Wei (College Station, TX)
Assignee:	Suzhou Kunpeng Biotech Co., Ltd. (Kunshan, Suzhou, CN)
Application Number:	15/638,145
Patent Claims:	1. A method for enhancing expression of a target peptide, the method comprising culturing a host cell transformed with an expression vector comprising a nucleic acid encoding a fusion protein that comprises a fusion carrier protein linked to the target peptide, wherein the fusion carrier protein has an amino acid sequence as set forth in Formula T1-A1-T2 (I), wherein T1 is absent, a Met, a His-tag, or at least one peptidic cleavage site, A1 is a superfolder green fluorescent protein, which has the amino acid sequence Ser-Lys-Gly-Glu-Glu-Leu-Phe-Thr-Gly-Val-Val-Pro-Ile-Leu-Val-Glu-Leu-Asp-G- ly-Asp-Val-Asn-Gly-His-Lys-Phe-Ser-Val-Arg-Gly-Glu-Gly-Glu-Gly-Asp-Ala-Thr- -Asn-Gly-Lys-Leu-Thr-Leu-Lys-Phe-Ile-Cys-Thr-Thr-Gly-Lys-Leu-Pro-Val-Pro-T- rp-Pro-Thr-Leu-Val-Thr-Thr-Leu-Thr-Tyr-Gly-Val-Gln-Cys-Phe-Ser-Arg-Tyr-Pro- -Asp-His-Met-Lys-Arg-His-Asp-Phe-Phe-Lys-Ser-Ala-Met-Pro-Glu-Gly-Tyr-Val-G- ln-Glu-Arg-Thr-Ile-Ser-Phe-Lys-Asp-Asp-Gly-Thr-Tyr-Lys-Thr-Arg-Ala-Glu-Val- -Lys-Phe-Glu-Gly-Asp-Thr-Leu-Val-Asn-Arg-Ile-Glu-Leu-Lys-Gly-Ile-Asp-Phe-L- ys-Glu-Asp-Gly-Asn-Ile-Leu-Gly-His-Lys-Leu-Glu-Tyr-Asn-Phe-Asn-Ser-His-Asn- -Val-Tyr-Ile-Thr-Ala-Asp-Lys-Gln-Lys-Asn-Gly-Ile-Lys-Ala-Asn-Phe-Lys-Ile-A- rg-His-Asn-Val-Glu-Asp-Gly-Ser-Val-Gln-Leu-Ala-Asp-His-Tyr-Gln-Gln-Asn-Thr- -Pro-Ile-Gly-Asp-Gly-Pro-Val-Leu-Leu-Pro-Asp-Asn-His-Tyr-Leu-Ser-Thr-Gln-S- er-Val-Leu-Ser-Lys-Asp-Pro-Asn-Glu-Lys-Arg-Asp-His-Met-Val-Leu-Leu-Glu-Phe- -Val-Thr-Ala-Ala-Gly-Ile-Thr-His-Gly-Met-Asp-Glu-Leu-Tyr-Lys (SEQ ID NO:1), or an amino acid sequence that is at least 90%, at least 95%, at least 97%, or at least 99% identical to SEQ ID NO:1, T2 is absent, a His-tag, or at least one peptidic cleavage site, provided that at most one of T1 and T2 is absent, under suitable conditions for expression of the expression vector, thereby producing the fusion protein encoded by the nucleic acid in bacterial inclusion bodies, wherein the suitable conditions comprise an inducer for inducing the host cell to express the expression vector, and wherein the expression level of the target peptide is enhanced as compared to a control where a fusion carrier protein is not used. 2. The method of claim 1, wherein the target peptide is selected from the group consisting of corticorelin, PTH, GLP-1 and its analogs exenatide and liraglutide, enfuvirtide, calcitonin, bivalirudin, ziconotide, sermorelin, somatorelin, secretin, teduglutide, proinsulin, hirudin, growth hormone, growth factors, growth hormone releasing factors, corticotropin, release factor, deslorelin, desmopressin, elcatonin, glucagons, leuprolide, leuteinizing hormone-releasing hormone, somatisation, thyrotropin-releasing hormone, triptorelin, vasoactive intestinal peptide, interferons, parathyroid hormone, BH3 peptides, and a beta-amyloidosis peptide or fragments thereof. 3. The method of claim 1, wherein the peptidic cleavage site is selected from the group consisting of Met, Cys, Pro, Asn, Glu, Tyr, Trp, Lys, Arg, Asn-Gly, Asp-Met-Gln-Asp-Ile (SEQ ID NO:31), Asp-Glu-Val-Asp-Ile (SEQ ID NO:32), Leu-Glu-Val-Asp-Ile (SEQ ID NO:33), Trp-Glu-His-Asp-Ile (SEQ ID NO:34), Leu-Glu-His-Asp-Ile (SEQ ID NO:35), Val-Glu-Ile-Asp-Ile (SEQ ID NO:36), Val-Glu-His-Asp-Ile (SEQ ID NO:37), Ile-Glu-Thr-Asp-Ile (SEQ ID NO:38), Leu-Glu-Thr-Asp-Ile (SEQ ID NO:39), Ile-Glu-Ala-Asp-Ile (SEQ ID NO:40), Asp-Asp-Asp-Asp-Lys (SEQ ID NO:41), Arg-Gly-Glu-Ile (SEQ ID NO:42), Arg-Gly-Asp-Ile (SEQ ID NO:43), Arg-Gly-Asp-Ala (SEQ ID NO:45), Ile-Glu-Pro-Asp-Ile (SEQ ID NO:46), Glu-Asn-Leu-Tyr-Phe-Gln-Gly (SEQ ID NO:3), and Glu-Asn-Leu-Tyr-Phe-Gln-Ser (SEQ ID NO:5). 4. The method of claim 1, wherein the peptidic cleavage site is selected from the group consisting of Met, Lys, Arg, Glu-Asn-Leu-Tyr-Phe-Gln-Gly (SEQ ID NO:3), and Glu-Asn-Leu-Tyr-Phe-Gln-Ser (SEQ ID NO:5). 5. The method of claim 1, wherein the His-tag is composed of three to eight histidine residues. 6. The method of claim 1, wherein the target peptide has a sequence between 10 and 200 amino acids in length. 7. The method of claim 1, wherein the target peptide has a sequence between 20 and about 82 amino acids in length. 8. The method of claim 1, wherein the fusion protein further comprises a peptide cleavage site between the fusion carrier protein and the target peptide. 9. The method of claim 1, wherein the expression vector comprising the nucleic acid is operably linked to a promoter for expression of said nucleic acid sequence coding for the fusion protein. 10. The method of claim 9, wherein the promoter is lac promoter, T7 promoter, Tac promoter, lamda promoter, pL promoter, trc promoter, or pBAD promoter.

Details for Patent 10,239,922

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2032-03-23